Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer

References

• 1. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol. Hepatol. 5(1), 42–54 (2020).
  MedlineGoogle Scholar
• 2. Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33(10), 1005–1020 (2022).
  Medline CASGoogle Scholar
• 3. Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294), 27–40 (2021).
  Medline CASGoogle Scholar
• 4. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).
  Medline CASGoogle Scholar
• 5. Gómez-Martin C, Garralda E, Echarri MJ et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J. Clin. Pathol. 65(8), 751–757 (2012).
  MedlineGoogle Scholar
• 6. Janjigian YY, Werner D, Pauligk C et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol. 23(10), 2656–2662 (2012).
  Medline CASGoogle Scholar
• 7. Shitara K, Bang Y-J, Iwasa S et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl. J. Med. 382(25), 2419–2430 (2020).
  Medline CASGoogle Scholar
• 8. Janjigian YY, Kawazoe A, Yañez P et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600(7890), 727–730 (2021).
  Medline CASGoogle Scholar
• 9. Sahin U, Koslowski M, Dhaene K et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14(23), 7624–7634 (2008).
  Medline CASGoogle Scholar
• 10. Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther. 14, 4361–4381 (2021).
  MedlineGoogle Scholar
• 11. Sahin U, Schuler M, Richly H et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur. J. Cancer 100, 17–26 (2018).
  Medline CASGoogle Scholar
• 12. Türeci Ö, Mitnacht-Kraus R, Wöll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 8(1), e1523096 (2019).
  MedlineGoogle Scholar
• 13. Sahin U, Türeci Ö, Manikhas G et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann. Oncol. 32(5), 609–619 (2021).
  Medline CASGoogle Scholar
• 14. Shitara K, Lordick F, Bang Y-J et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401(10389), 1655–1668 (2023).
  Medline CASGoogle Scholar
• 15. Xu R, Shitara K, Ajani JA et al. Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2- locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary phase 3 results from GLOW. JCO 41(Suppl. 36), 405736–405736 (2023).
  Google Scholar
• 16. Shitara K, Yamaguchi K, Shoji H et al. Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas. JCO 41(Suppl. 16), TPS4173–TPS4173 (2023).
  Google Scholar
• 17. Pellino A, Brignola S, Riello E et al. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J. Pers Med. 11(11), 1095 (2021).
  MedlineGoogle Scholar
• 18. Kubota Y, Kawazoe A, Mishima S et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8(1), 100762 (2023).
  Medline CASGoogle Scholar
• 19. Moran D, Maurus D, Rohde C, Arozullah A. Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples. Ann. Oncol. 29, viii32 (2018).
  Google Scholar
• 20. Schuler MH, Al-Batran S-E, Zvirbule Z et al. Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: results from the FAST study. JCO 35(Suppl. 15), 4038–4038 (2017).
  Google Scholar